Literature DB >> 2108463

Using seroprevalence data in managing public health programs.

I M Onorato1, T S Jones, W R Forrester.   

Abstract

An objective of the Centers for Disease Control (CDC) family of HIV seroprevalence surveys, conducted by State and local health departments, is the collection of seroprevalence data that may be useful in managing public health programs. In prevention programs, seroprevalence data may be used in allocating resources, in determining the types and amount of education, counseling, and testing services offered, and in identifying access points for HIV-infected persons for medical followup and care. Over time, data will be useful in detecting and following trends in HIV infection and in evaluating the impact of program activities to prevent HIV infection. No single seroprevalence survey is representative of the entire population of a metropolitan area. Each type of survey has strengths and limitations that must be considered when interpreting seroprevalence data. However, results from the family of surveys are the best available data because they are relatively unaffected by self-selection bias, they are standardized, and the information is collected over time. Characterization of the population surveyed and adherence to standard CDC protocols improve the quality of the data. Consultants in health departments and at CDC form a network for providing technical support and disseminating data to health care providers and program managers.

Entities:  

Mesh:

Year:  1990        PMID: 2108463      PMCID: PMC1580051     

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  9 in total

1.  Targeting AIDS prevention and treatment toward HIV-1-infected persons. The concept of early intervention.

Authors:  D P Francis; R E Anderson; M E Gorman; M Fenstersheib; N S Padian; K W Kizer; M A Conant
Journal:  JAMA       Date:  1989-11-10       Impact factor: 56.272

2.  Determining HIV seroprevalence among women in women's health clinics.

Authors:  D M Allen; N C Lee; S L Schulz; M Pappaioanou; T J Dondero; I M Onorato
Journal:  Public Health Rep       Date:  1990 Mar-Apr       Impact factor: 2.792

3.  HIV seroprevalence surveys in sexually transmitted disease clinics.

Authors:  I M Onorato; E McCray; M Pappaioanou; R Johnson; S Aral; A M Hardy; T J Dondero
Journal:  Public Health Rep       Date:  1990 Mar-Apr       Impact factor: 2.792

4.  Estimating HIV levels and trends among patients of tuberculosis clinics.

Authors:  E McCray; I M Onorato; B I Miller; T J Dondero; A B Bloch
Journal:  Public Health Rep       Date:  1990 Mar-Apr       Impact factor: 2.792

5.  HIV seroprevalence surveys of childbearing women--objectives, methods, and uses of the data.

Authors:  M Pappaioanou; J R George; W H Hannon; M Gwinn; T J Dondero; G F Grady; R Hoff; A D Willoughby; A Wright; A C Novello
Journal:  Public Health Rep       Date:  1990 Mar-Apr       Impact factor: 2.792

6.  HIV seroprevalence surveys in drug treatment centers.

Authors:  T S Jones; D M Allen; I M Onorato; L R Petersen; T J Dondero; M Pappaioanou
Journal:  Public Health Rep       Date:  1990 Mar-Apr       Impact factor: 2.792

7.  HIV seroprevalence in newborns in New York State.

Authors:  L F Novick; D Berns; R Stricof; R Stevens; K Pass; J Wethers
Journal:  JAMA       Date:  1989 Mar 24-31       Impact factor: 56.272

8.  Monitoring the levels and trends of HIV infection: the Public Health Service's HIV surveillance program.

Authors:  T J Dondero; M Pappaioanou; J W Curran
Journal:  Public Health Rep       Date:  1988 May-Jun       Impact factor: 2.792

9.  Comparison of HIV-antibody prevalence in patients consenting to and declining HIV-antibody testing in an STD clinic.

Authors:  H F Hull; C J Bettinger; M M Gallaher; N M Keller; J Wilson; G J Mertz
Journal:  JAMA       Date:  1988-08-19       Impact factor: 56.272

  9 in total
  3 in total

1.  HIV seroprevalence surveys in drug treatment centers.

Authors:  T S Jones; D M Allen; I M Onorato; L R Petersen; T J Dondero; M Pappaioanou
Journal:  Public Health Rep       Date:  1990 Mar-Apr       Impact factor: 2.792

Review 2.  HIV education for the deaf, a vulnerable minority.

Authors:  J R Peinkofer
Journal:  Public Health Rep       Date:  1994 May-Jun       Impact factor: 2.792

3.  Applications of data from the CDC Family of Surveys.

Authors:  I M Onorato; M Gwinn; T J Dondero
Journal:  Public Health Rep       Date:  1994 Mar-Apr       Impact factor: 2.792

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.